These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 16980516

  • 1. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study.
    Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S.
    Heart; 2007 Mar; 93(3):350-4. PubMed ID: 16980516
    [Abstract] [Full Text] [Related]

  • 2. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease.
    Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S.
    Heart; 2005 Nov; 91(11):1447-52. PubMed ID: 15761050
    [Abstract] [Full Text] [Related]

  • 3. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease.
    Diller GP, Dimopoulos K, Kaya MG, Harries C, Uebing A, Li W, Koltsida E, Gibbs JS, Gatzoulis MA.
    Heart; 2007 Aug; 93(8):974-6. PubMed ID: 17639112
    [Abstract] [Full Text] [Related]

  • 4. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.
    Sitbon O, Beghetti M, Petit J, Iserin L, Humbert M, Gressin V, Simonneau G.
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():25-31. PubMed ID: 16919007
    [Abstract] [Full Text] [Related]

  • 5. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?
    van Loon RL, Hoendermis ES, Duffels MG, Vonk-Noordegraaf A, Mulder BJ, Hillege HL, Berger RM.
    Am Heart J; 2007 Oct; 154(4):776-82. PubMed ID: 17893008
    [Abstract] [Full Text] [Related]

  • 6. Therapy for pulmonary arterial hypertension due to congenital heart disease and Down's syndrome.
    D'Alto M, Romeo E, Argiento P, D'Andrea A, Sarubbi B, Correra A, Scognamiglio G, Papa S, Bossone E, Calabrò R, Vizza CD, Russo MG.
    Int J Cardiol; 2013 Apr 15; 164(3):323-6. PubMed ID: 21802156
    [Abstract] [Full Text] [Related]

  • 7. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.
    Lunze K, Gilbert N, Mebus S, Miera O, Fehske W, Uhlemann F, Mühler EG, Ewert P, Lange PE, Berger F, Schulze-Neick I.
    Eur J Clin Invest; 2006 Sep 15; 36 Suppl 3():32-8. PubMed ID: 16919008
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect.
    D'Alto M, Vizza CD, Romeo E, Badagliacca R, Santoro G, Poscia R, Sarubbi B, Mancone M, Argiento P, Ferrante F, Russo MG, Fedele F, Calabrò R.
    Heart; 2007 May 15; 93(5):621-5. PubMed ID: 17135220
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Endothelin receptor antagonists are an effective long term treatment option in pulmonary arterial hypertension associated with congenital heart disease with or without trisomy 21.
    Kermeen FD, Franks C, O'Brien K, Seale H, Hall K, McNeil K, Radford D.
    Heart Lung Circ; 2010 Oct 15; 19(10):595-600. PubMed ID: 20728407
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
    Denton CP, Humbert M, Rubin L, Black CM.
    Ann Rheum Dis; 2006 Oct 15; 65(10):1336-40. PubMed ID: 16793845
    [Abstract] [Full Text] [Related]

  • 15. A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease.
    Durongpisitkul K, Jakrapanichakul D, Sompradikul S.
    J Med Assoc Thai; 2008 Feb 15; 91(2):196-202. PubMed ID: 18389984
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy.
    Schulze-Neick I, Gilbert N, Ewert R, Witt C, Gruenig E, Enke B, Borst MM, Lange PE, Hoeper MM.
    Am Heart J; 2005 Oct 15; 150(4):716. PubMed ID: 16209972
    [Abstract] [Full Text] [Related]

  • 19. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W.
    J Am Coll Cardiol; 2010 May 04; 55(18):1915-22. PubMed ID: 20430262
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.